Englewood Cliffs, New Jersey, USA: Prentice Hall
The Phase 2b OPTIONS trial 536 obese subjects, randomized to receive 0.25, 0.5, or 1 mg/day oral AOD-9604 or placebo over 24 weeks failed to demonstrate statistically significant weight loss at any dose tested
Why people explore AOD 9604/MOTS-C AOD 9604 drives lipolysis to break down existing fat stores
Methylcobalamin and adenosylcobalamin are the two forms of active vitamin B12 used by the body
Safety: what we know, what we dont What clinical trial safety reviews suggest The clinical safety review literature reports several reassuring signals: No meaningful increase in IGF-1 in monitored long-term studies (jofem.org) No clear negative effect on carbohydrate metabolism in testing described (contrast with full hGH) (jofem.org) No clear immunogenicity signal (e.g., anti-AOD antibodies) in the subset assessed in those trials (jofem.org) The major limitation: long-term real-world certainty is thin The problem with many peptides is not that everything is dangerousits that the certainty level is often lower than patients assume
If anything feels off after your shot, its always okay to check in with your doctor or clinic
